KRAS and pancreatic ductal adenocarcinoma: KRAS mutations are very prevalent in pancreatic ductal adenocarcinoma (PDAC) and is associated with a very poor prognosis.121 One study showed that the presence of a KRAS mutation correlated with the overexpression of BET proteins including BRD2, BRD3 and BRD4 in PDAC.81 In this scenario, JQ1 and histone deacetylase (HDAC) inhibitors were found to act in synergy in vivo.